Oral and Anal Swab Sampling in Patients With HPV Positivity (Oral Anal HPV)
Evaluation of Oropharyngeal and Anal Swab Samples in Patients With HPV Positivity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Gaziantep, Turkey, 27010
- Gaziantep Cengiz Gokcek Women's, Obstetrics and Pediatrics Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- HPV-positive women presenting to the Obstetrics and Gynecology clinic, whose cervical pathology results were reported as CIN 1, CIN 2, and CIN 3
Exclusion Criteria:
- HPV-negative women
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Swab Sampling
Oropharyngeal and anal swab samples are obtained.
|
Oropharyngeal and anal swab samples are evaluated in the Microbiology laboratory for the existence of HPV.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oropharyngeal Swab Sample - HPV Testing
Time Frame: 1 month
|
Presence of HPV will be tested
|
1 month
|
|
Anal Swab Sample - HPV Testing
Time Frame: 1 month
|
Presence of HPV
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oropharyngeal Swab Sample - HPV Testing (if positive)
Time Frame: 1 month
|
Type of HPV
|
1 month
|
|
Anal Swab Sample - HPV Testing (if positive)
Time Frame: 1 month
|
Type of HPV
|
1 month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Neslihan Bayramoglu Tepe, Doctor of Medicine, University of Gaziantep
- Study Chair: Ozan Dogan, Prof. Dr., Istanbul Nisantasi University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Number 362
- TF.HZP.23.31 (Other Grant/Funding Number: Gaziantep University Scientific Research Project support program)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.